White House Schedules Additional 2026 Cannabis Enforcement Policy Meetings
The White House has scheduled more 2026 cannabis enforcement policy meetings to discuss federal regulation updates. These meetings affect patient access and clinician liability regarding cannabis products. Stakeholders should monitor these developments…
DOJ Cannabis Rescheduling Update Requested by Congressman (Newsletter: March 30, 2026)
The DOJ cannabis rescheduling update requested by congressman highlights ongoing federal policy deliberations in 2026. Rescheduling cannabis could transform clinical research and prescribing practices. Clinicians should monitor these regulatory changes…
Rescheduling Cannabis Under the Controlled Substances Act | Regulatory Review
Rescheduling cannabis regulatory impact under the Controlled Substances Act could transform research and clinical practice. Lower scheduling may enable more rigorous trials and standardized product development. This shift is crucial for advancing…
Innovative Industrial Properties: Undervalued Amid Cannabis Rescheduling Milestone
The cannabis rescheduling milestone marks a pivotal change in federal law, impacting medical cannabis research and clinical practice. This shift to Schedule III could accelerate pharmaceutical development and alter regulatory frameworks. Understanding…
Congressman Demands DOJ Update on Marijuana Rescheduling
The marijuana rescheduling update remains pending as the DOJ has yet to respond three months after the executive order. This delay impacts federal cannabis policy and clinical practice by limiting research and insurance coverage. Clinicians face ongoing…
Army Adopts New Cannabis Policy to Boost Recruitment (Newsletter: March 26, 2026)
The 2026 military cannabis policy changes mark a significant shift in army recruitment strategies. These changes affect veteran healthcare and civilian-military care transitions. Clinicians should monitor evolving policies to better serve military and…
White House Schedules Meeting On Cannabis Products Enforcement Policy For Next Week
The White House has scheduled a meeting on cannabis products enforcement policy, signaling potential federal regulatory changes. This policy directly affects patient access to cannabis medications and clinical practice. Healthcare providers should…
Congress Should Stop Scheduling Substances Without Consulting the Science
Legislative scheduling decisions cannabis create barriers to evidence-based medicine by bypassing scientific review. This limits physicians' ability to recommend appropriate treatments and restricts research. Reforming federal cannabis scheduling is…